Explore daily insights on
SELLAS Life Sciences gains 38.8% in a week as Phase 3 trial nears readout
- SELLAS Life Sciences shares have experienced a major upward run as investors anticipate clinical trial results.
- The stock rose 38.8% in a week to close at $7.29 on May 18, up from $5.25 on May 11.
- This move follows Q1 earnings and confirmation that its Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 3 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
Close price rose from $5.25 (May 11) to $7.29 (May 18) in daily_prices. Q1 earnings and trial update news published May 13-15, 2026, with continuing momentum on May 22, 2026.